Immunotherapy using purififi ed protein derivative in the treatment of warts: An open uncontrolled trial.
Indian J Dermatol Venereol Leprol
;
2016 Jan-Feb; 82(1): 42-46
Article
in English
| IMSEAR
| ID: sea-169977
ABSTRACT
Background:
Warts are known to clear spontaneously with the development of cell-mediated immunity (CMI) to the virus. Purifi ed protein derivative (PPD) of tuberculin bacilli has been used as a non-specific stimulant of CMI to achieve this outcome.Aim:
To study the effect of PPD in the treatment of warts.Methods:
Patients with difficult-to-treat warts were selected for immunotherapy. Each patient received 2.5 TU of PPD intralesionally in a few warts. A total of four sessions were given at 2 weekly intervals and patients were followed up for 6 months after the last dose.Results:
Sixty-one patients were recruited of which 55 completed 6 months follow up and were available for analysis. Of these, 25 had verruca vulgaris, 18 had verruca plana and 12 had plantar warts. Forty two (76%) patients showed complete clearance after four sessions while the remaining 13 (24%) patients were non-responders. One patient developed a recurrence after total clearance during the follow-up period. Adverse effects were erythema, edema and pain at the site of injections.Limitations:
As this was an uncontrolled trial, there is no comparison with a non-intervention group. Also, a Mantoux test was not done due to practical difficulties.Conclusion:
Immunotherapy with PPD is helpful in the treatment of cutaneous warts.
Full text:
Available
Index:
IMSEAR (South-East Asia)
Language:
English
Journal:
Indian J Dermatol Venereol Leprol
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS